

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6162662

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST

**CONVEYING PARTY DATA**

Name	Execution Date
PERCEPTIVE CREDIT HOLDINGS II, LP	06/19/2020

**RECEIVING PARTY DATA**

<b>Name:</b>	ATHENEX, INC.
<b>Street Address:</b>	CONVENTUS BUILDING, 1001 MAIN STREET, SUITE 600
<b>City:</b>	BUFFALO
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	14203

**PROPERTY NUMBERS Total: 29**

Property Type	Number
Patent Number:	8980890
Patent Number:	8003641
Application Number:	12738528
Application Number:	15921890
Application Number:	15918100
Application Number:	15895244
Application Number:	12595357
Patent Number:	8901297
Patent Number:	9655903
Application Number:	15676203
Patent Number:	7968574
Patent Number:	7838542
Patent Number:	8598169
Patent Number:	9556120
Patent Number:	7935697
Patent Number:	7300931
Application Number:	15408098
Application Number:	15387322
Patent Number:	8124605
Patent Number:	7939529

PATENT

Property Type	Number
Patent Number:	8236799
Application Number:	62657444
Application Number:	62555390
Patent Number:	8309549
Patent Number:	8293739
Patent Number:	9580387
Patent Number:	8748423
Patent Number:	9926273
Patent Number:	7851470

**CORRESPONDENCE DATA**

**Fax Number:** (415)693-2222  
*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 4156932000  
**Email:** crhem@cooley.com  
**Correspondent Name:** COOLEY LLP  
**Address Line 1:** 101 CALIFORNIA STREET, 5TH FLOOR  
**Address Line 4:** SAN FRANCISCO, CALIFORNIA 94111

<b>ATTORNEY DOCKET NUMBER:</b>	322169-102
<b>NAME OF SUBMITTER:</b>	C. RHEM
<b>SIGNATURE:</b>	/CR/
<b>DATE SIGNED:</b>	06/19/2020

**Total Attachments: 7**  
source=Athenex - Perceptive - Patent Release Executed#page1.tif  
source=Athenex - Perceptive - Patent Release Executed#page2.tif  
source=Athenex - Perceptive - Patent Release Executed#page3.tif  
source=Athenex - Perceptive - Patent Release Executed#page4.tif  
source=Athenex - Perceptive - Patent Release Executed#page5.tif  
source=Athenex - Perceptive - Patent Release Executed#page6.tif  
source=Athenex - Perceptive - Patent Release Executed#page7.tif

## **RELEASE OF SECURITY INTEREST IN PATENT COLLATERAL**

This RELEASE OF SECURITY INTEREST IN PATENT COLLATERAL, dated as of June 19, 2020 (this "**Release**"), is made by PERCEPTIVE CREDIT HOLDINGS II, LP ("**Lender**") in favor of ATHENEX, INC. ("**Grantor**"), as follows:

### **WITNESSETH**

WHEREAS, pursuant to the Patent Security Agreement, dated as of July 3, 2018 ("**Agreement**"), as collateral security for the payment and performance in full of all the obligations, liabilities and indebtedness owing to Lender, Grantor pledged and granted to Lender, for the benefit of Lender and the other Secured Parties (as set forth in the Credit Agreement and Guaranty dated as of June 30, 2018 (as amended by Amendment No. 1 to Credit Agreement dated as of April 22, 2019 and Amendment No. 2 to Credit Agreement dated as of August 5, 2019 and as otherwise amended, amended and restated or otherwise modified from time to time prior to the date hereof, the "**Loan Agreement**"), a lien on and security interest in all of the right, title and interest of such Grantor in and to the Patent Collateral (as defined in the Agreement), including, without limitation those Patents (as defined in the Loan Agreement) of such Grantor listed on Schedule I attached hereto; and

WHEREAS, pursuant to the Payoff Letter, dated June 19, 2020 ("**Payoff Letter**"), Lender has released, in favor of the Grantor, all of its security interest, right, title and interest in, to and under the Patent Collateral, including, without limitation, those Patents of such Grantor listed on Schedule I attached hereto.

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged and as set forth in the Payoff Letter, Lender hereby terminates the Agreement and terminates, releases and re-conveys to Grantor, without recourse, any and all of Lender's right, title and interest in and to its security interest in the Patent Collateral, including, without limitation, those Patents of such Grantor listed on Schedule I attached hereto.

Lender confirms that this Release may be filed along with any other necessary documentation with the United States Patent and Trademark Office ("**USPTO**") to evidence the release granted herein, as desired by Grantor. Lender authorizes Grantor, any of the Grantors' authorized representatives, any new lender to the Grantor or any of such new lender's authorized representatives to (i) record this Release with the USPTO and other applicable registry at the sole expense of Grantor and (ii) file UCC financing statement terminations with the applicable filing office in order to memorialize the release of any Lien on, or security interest in, the Patent Collateral. Lender agrees to provide Grantor with any information and additional authorization necessary to effect the release of the security interest in the Patent Collateral, upon a written request therefor and at the Grantor's sole expense.

The validity, interpretation and enforcement of this Release and any dispute arising out of the relationship between the parties hereto, whether in contract, tort, equity or otherwise, shall be governed by and construed in accordance with the terms and conditions of the Payoff Letter and this Release is expressly subject thereto.

Capitalized terms used but not defined herein shall have the meanings given to them in the Agreement.

Delivery of an executed signature page to this Release by facsimile or electronic transmissions (including .pdf file) shall be effective as delivery of an original signature.

[Signature Page Follows]

IN WITNESS WHEREOF, Lender has caused this Release to be duly executed and delivered by its duly authorized officer as of the date first written above.

**PERCEPTIVE CREDIT HOLDINGS II, LP**

**By: PERCEPTIVE CREDIT OPPORTUNITIES  
GP, LLC, its general partner**

By: S. Dixit  
Name: Sandeep Dixit  
Title: Chief Credit Officer

By: \_\_\_\_\_  
Name: Sam Chawla  
Title: Portfolio Manager

IN WITNESS WHEREOF, Lender has caused this Release to be duly executed and delivered by its duly authorized officer as of the date first written above.

**PERCEPTIVE CREDIT HOLDINGS II, LP**

**By: PERCEPTIVE CREDIT OPPORTUNITIES  
GP, LLC, its general partner**

By: \_\_\_\_\_

Name: Sandeep Dixit

Title: Chief Credit Officer

By:  \_\_\_\_\_

Name: Sam Chawla

Title: Portfolio Manager

**SCHEDULE I TO  
RELEASE OF SECURITY INTEREST  
IN PATENT COLLATERAL**

**See Attached.**

## PATENTS

Patents and Patent Applications

Title	Reg. #	Appl. #	Publ. #	Jurisdiction	Owner
COMPOSITIONS AND METHODS OF TREATING CELL PROLIFERATION DISORDERS	8,980,890	12/950,764	20110065705	U.S.	Athenex, Inc.
COMPOSITIONS AND METHODS OF TREATING CELL PROLIFERATION DISORDERS	8,003,641	11/796,200	20070197783	U.S.	Athenex, Inc.
PHARMACEUTICAL COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF		12/738,528	20100278776	U.S.	Athenex, Inc.
BIARYL PIPERIDINE AMIDE COMPOUNDS AND METHODS OF USE THEREOF		15/921,890		U.S.	Athenex, Inc.
METHODS OF TREATING AND/OR PREVENTING ACTINIC KERATOSIS		15/918,100		U.S.	Athenex, Inc.
COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE		15/895,244	20180170875	U.S.	Athenex, Inc.
BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE		12/595,357	20100249130	U.S.	Athenex, Inc.
COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF	8,901,297	13/614,063	20130210822	U.S.	Athenex, Inc.
COMPOSITIONS AND METHODS OF TREATING CELL PROLIFERATION DISORDERS	9,655,903	14/658,736	20150182532	U.S.	Athenex, Inc.
BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE		15/676,203	20180042934	U.S.	Athenex, Inc.
BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE	7,968,574	11/480,174	20070015752	U.S.	Athenex, Inc.
BICYCLIC COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE	7,838,542	11/480,163	20080004241	U.S.	Athenex, Inc.
BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE	8,598,169	13/540,940	20120270874	U.S.	Athenex, Inc.
COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF	9,556,120	14/554,495	20150315147	U.S.	Athenex, Inc.
COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF	7,935,697	12/468,694	20090318450	U.S.	Athenex, Inc.
COMPOSITIONS FOR TREATING CELL PROLIFERATION DISORDERS	7,300,931	11/321,419	20060160800	U.S.	Athenex, Inc.
BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE		15/408,098	20170196874	U.S.	Athenex, Inc.
COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF		15/387,322	20170101378	U.S.	Athenex, Inc.



Title	Reg. #	Appl. #	Publ. #	Jurisdiction	Owner
COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE	8,124,605	12/217,721	20090149510	U.S.	Athenex, Inc.
PROCESS FOR THE PREPARATION OF COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF	7,939,529	12/154,056	20080287436	U.S.	Athenex, Inc.
BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE	8,236,799	13/152,949	20110237586	U.S.	Athenex, Inc.
THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED PACLITAXEL AND A P-GP INHIBITOR FOR THE TREATMENT OF ANGIOSARCOMA		62/657,444		U.S.	Athenex, Inc.
THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED PACLITAXEL AND A P-GP INHIBITOR FOR THE TREATMENT OF ANGIOSARCOMA		62/657,444		U.S.	Athenex, Inc.
SOLID FORMS OF 2-(5-(4-(2-MORPHOLINOETHOXY)PHENYL)PYRIDIN-2-YL)-N-BENZYLACETAMIDE		62/555,390		U.S.	Athenex, Inc.
COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF	8,309,549	13/094,679	20110201612	U.S.	Athenex, Inc.
PROCESS FOR THE PREPARATION OF COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF	8,293,739	13/094,667	20110201611	U.S.	Athenex, Inc.
BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE	9,580,387	14/094,027	20140213587	U.S.	Athenex, Inc.
COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CANCER	8,748,423	13/046,533	20110281872	U.S.	Athenex, Inc.
COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE	9,926,273	14/015,030	20140066445	U.S.	Athenex, Inc.
COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE	7,851,470	12/005,792	20080221102	U.S.	Athenex, Inc.